Natalya (Desogestrel, Ethinylestradiol)

Desogestrel, the active ingredient in Natalya, is a combined oral contraceptive presented as a tablet for oral use. Together with ethinylestradiol, it works to prevent pregnancy by suppressing ovulation, thickening cervical mucus, and modifying the endometrial lining, providing reliable contraception for women of reproductive age. The formulation follows European Union standards for quality, efficacy, and safety, and is prescribed by healthcare professionals as part of family planning strategies.

GNH USA supplies Natalya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Natalya, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

Contraception: Prevents unintended pregnancy in women of reproductive age. Family planning: Supports planned timing of pregnancies as part of a birth‑control strategy. Hormonal birth control: Provides reliable suppression of ovulation through combined estrogen‑progestin action.

Natalya may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting or irregular bleeding

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke - Severe allergic reaction (anaphylaxis)

Before prescribing Natalya, clinicians should consider several safety aspects.

Assess cardiovascular risk: Evaluate personal and family history of thromboembolic disorders before initiating therapy. Avoid smoking: Women over 35 who smoke should not use combined oral contraceptives. Monitor blood pressure: Regular checks are advised as hypertension may be worsened. Consider liver function: Use with caution in patients with hepatic impairment. Pregnancy testing: Ensure the patient is not pregnant prior to starting the medication. Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture and light.

Natalya can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): Reduce hormone levels and increase risk of contraceptive failure. - Rifampicin and other strong CYP3A4 inducers: Significantly lower contraceptive effectiveness. - Protease inhibitors (e.g., ritonavir): May raise hormone concentrations, heightening side‑effect risk.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline): May slightly diminish efficacy. - Antifungal agents (e.g., fluconazole): Can increase hormone levels, requiring monitoring. - Herbal supplements such as St. John’s wort: May lower contraceptive effectiveness through enzyme induction.